Multiparametric Analysis of Cell-Free DNA in Melanoma Patients

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Salvianti, Francesca ^a   Pinzani, Pamela ^a   Verderio, Paolo ^b   Ciniselli, Chiara Maura ^b   Massi, Daniela ^a   de Giorgi, Vincenzo ^a   Grazzini, Marta ^a   Pazzagli, Mario ^a   Orlando, Claudio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CELL FREE DNA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRAF GENE; CANCER PATIENT; CONTROLLED STUDY; CUTANEOUS MELANOMA; DNA METHYLATION; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PREDICTION; PROMOTER REGION; RASSF1A GENE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; DNA; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; ROC CURVE; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84870266511     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049843     Document Type: Article

References (40)

1. Hodgson DR, Wellings R, Orr MC, McCormack R, Malone M, et al. (2010) Circulating tumour-derived predictive biomarkers in oncology. Drug Discov Today 15: 98-101.
2. Fleischhacker M, Schmidt B, (2007) Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 1775: 181-232.
3. Jung K, Fleischhacker M, Rabien A, (2010) Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta 411: 1611-24.
4. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, et al. (2003) Increased plasma DNA integrity in cancer patients. Cancer Res 63: 3966-8.
5. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, et al. (2006) Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 24: 4270-6.
6. Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, et al. (2006) Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 52: 1062-9.
7. Hanley R, Rieger-Christ KM, Canes D, Emara NR, Shuber AP, et al. (2006) DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer. Clin Cancer Res 12: 4569-74.
8. Hauser S, Zahalka T, Ellinger J, Fechner G, Heukamp LC, et al. (2010) Cell-free circulating DNA: Diagnostic value in patients with renal cell cancer. Anticancer Res 30: 2785-9.
9. Jiang WW, Zahurak M, Goldenberg D, Milman Y, Park HL, et al. (2006) Increased plasma DNA integrity index in head and neck cancer patients. Int J Cancer 119: 2673-6.
10. Tomita H, Ichikawa D, Ikoma D, Sai S, Tani N, et al. (2007) Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res 27: 2737-41.
11. Dhomen N, Marais R, (2007) New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17: 31-9.
12. Huang PH, Marais R, (2009) Cancer: Melanoma troops massed. Nature 459: 336-7.
13. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-54.
14. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20.
15. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J, (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9: 6483-8.
16. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 364: 2507-16.
17. Daniotti M, Vallacchi V, Rivoltini L, Patuzzo R, Santinami M, et al. (2007) Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer 120: 2439-44.
18. Yancovitz M, Yoon J, Mikhail M, Gai W, Shapiro RL, et al. (2007) Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn 9: 178-83.
19. Donninger H, Vos MD, Clark GJ, (2007) The RASSF1A tumor suppressor. J Cell Sci 120: 3163-72.
20. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS, (2003) Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 63: 1639-43.
21. Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, et al. (2009) CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 15: 1801-7.
22. Hoon DS, Bostick P, Kuo C, Okamoto T, Wang HJ, et al. (2000) Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 60: 2253-7.
23. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, et al. (2006) Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol 126: 422-31.
24. Mori T, O'Day SJ, Umetani N, Martinez SR, Kitago M, et al. (2005) Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 23: 9351-8.
25. Koyanagi K, Mori T, O'Day SJ, Martinez SR, Wang HJ, et al. (2006) Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res 66: 6111-7.
26. Pinzani P, Salvianti F, Zaccara S, Massi D, De Giorgi V, et al. (2011) Circulating cell-free DNA in plasma of melanoma patients: Qualitative and quantitative considerations. Clin Chim Acta 412: 2141-5.
27. Lehmann U, Glöckner S, Kleeberger W, vonWasielewski HF, Kreipe, (2000) Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 156: 1855-64.
28. Pinzani P, Salvianti F, Cascella R, Massi D, De Giorgi V, et al. (2010) Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients. Clin Chim Acta 411: 1319-24.
29. Chan KC, Ding C, Gerovassili A, Yeung SW, Chiu RW, et al. (2006) Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 52: 2211-8.
30. Hollander M, Wolfe DA (1999) Nonparametric Statistical Methods, Second ed. New York: John Wiley & Sons.
31. Hosmer DW, Lemeshow S (1989) Applied Logistic Regression. New York: John Wiley & Sons.
32. Durrleman S, Simon R, (1989) Flexible regression models with cubic splines. Stat Med 8: 551-61.
33. Hanley JA, McNeil BJ, (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36.
34. Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P, et al. (1996) Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 69: 205-11.
35. Schwarzenbach H, Hoon DS, Pantel K, (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11: 426-37.
36. Pinsky PF, Zhu CS, (2011) Building Multi-Marker Algorithms for Disease Prediction-The Role of Correlations Among Markers. Biomarker Insights 6: 83-93.
37. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, et al. (2005) First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 353: 2001-11.
38. Schneider E, Mizejewski G, (2007) Multi-marker testing for cancer: what can we learn from modern prenatal testing for Trisomy-21. Cancer Inform 2: 44-7.
39. Mead R, Duku M, Bhandari P, Cree IA, (2011) Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer 105: 239-45.
40. Verderio P, Mangia A, Ciniselli CM, Tagliabue P, Paradiso A, (2010) Biomarkers for Early Cancer Detection- Methodological Aspects. Breast Care 5: 62-65.